Gesundheit Benjamin, Ben-David Eliel, Posen Yehudit, Ellis Ronald, Wollmann Guido, Schneider E Marion, Aigner Karl, Brauns Lars, Nesselhut Thomas, Ackva Ingrid, Weisslein Christine, Thaller Arno
Rapo Yerape Ltd., Jerusalem, Israel.
Department of Radiology, Shaare Zedek Medical Center, Jerusalem, Israel.
Front Oncol. 2020 May 14;10:702. doi: 10.3389/fonc.2020.00702. eCollection 2020.
Glioblastoma multiforme (GBM) remains an incurable condition, associated with a median survival time of 15 months with best standard of care and 5-year survival rate of <10%. We report on four GBM patients on combination treatment regimens that included oncolytic virus (OV) immunotherapy, who achieved clinical and radiological responses with long-term survival, thus far, of up to 14 years, and good quality of life. We discuss the radiological findings that provide new insights into this treatment, the scientific rationale of this innovative and promising therapy, and considerations for future research.
多形性胶质母细胞瘤（GBM）仍然是一种无法治愈的疾病，在最佳标准治疗下，其平均生存时间为15个月，5年生存率小于10%。我们报告了4例接受包括溶瘤病毒（OV）免疫疗法在内的联合治疗方案的GBM患者，这些患者实现了临床和影像学反应，目前已获得长达14年的长期生存，且生活质量良好。我们讨论了为这种治疗提供新见解的影像学发现、这种创新且有前景的疗法的科学原理以及对未来研究的考量。
